

A clinical study to evaluate the long-term safety of daratumumab in combination with standard bone marrow cancer treatment regimens

Submission date 27/09/2023	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/09/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/10/2024	Condition category Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Janssen Cilag International NV, the sponsor, is running a Phase 3b, multicentre, open-label Daratumumab long-term extension study, designed to collect long-term safety data for participants treated with daratumumab, and to provide ongoing access to daratumumab and other treatment for patients who are currently enrolled in daratumumab or other multiple myeloma program studies that have been completed according to the parent study, are actively receiving treatment, and who continue to benefit from treatment.

Daratumumab has been investigated in multiple myeloma studies as an IV infusion and by SC injection by itself and in combination with other therapies. Daratumumab IV is approved for people to receive in over 90 countries for the treatment of multiple myeloma. Daratumumab SC is approved for people to receive in over 50 countries for the treatment of multiple myeloma.

Daratumumab is being developed for the treatment of participants with multiple myeloma including newly diagnosed, relapsed/refractory, and smoldering multiple myeloma, participants with aberrant plasma cells in systemic light chain amyloidosis, and pediatric participants with acute lymphocytic leukemia.

Daratumumab will be administered through:

- an IV infusion where the needle is put into a vein of the arm through a small tube attached to a needle, or
- a SC injection where the medication is given in the abdomen and manually injected through a small tube or needle that goes directly under the skin.

This study will evaluate if long-term treatment with daratumumab may cause hepatitis B virus reactivation. Reactivation occurs when the hepatitis B virus becomes active after a long period of being inactive in the body. This can occur when the immune system becomes weakened and leads to other medical problems.

Who can participate?

About 500 patients will take part in this study worldwide, all from different previous Janssen studies.

What does the study involve?

Participants will receive the same treatment as they received in their previous research study during Screening and the Treatment Period.

For any participant receiving daratumumab IV, the study doctor will review the option to change to daratumumab SC on the first day of any cycle.

What are the possible benefits and risks of participating?

The potential risks and burdens for this study are provided in the Participant Information Sheet and Informed Consent Form(s) (PIS-ICF[s]). The participants will therefore be informed about these risks and burdens prior to taking part in the study. Due to the character limit for this question please refer to the PIS-ICF(s) for the risks and burdens. The management of these risks and burdens is presented below. Section 2.3.1 of the Protocol also outlines risks for study participation.

MANAGEMENT OF RISKS

Safety evaluations will be performed as clinically indicated and according to local institutional practice.

Where is the study run from?

Janssen Cilag International NV (Netherlands)

When is the study starting and how long is it expected to run for?

January 2022 to April 2026

Who is funding the study?

Janssen Cilag International NV (Netherlands)

Who is the main contact?

supratik.basu@nhs.net

Study website

<https://globaltrialfinder.janssen.com/trial/CR109200>

Contact information

Type(s)

Scientific

Contact name

Mr Alan Alty

Contact details

500 South Oak Way
Green Park

Reading
United Kingdom
RG2 6AD

Type(s)

Principal Investigator

Contact name

Dr Supratik Basu

Contact details

New Cross Hospital
Wolverhampton Road
Wolverhampton
United Kingdom
WV10 0QP
+44 791 7106288
supratik.basu@nhs.net

Additional identifiers

EudraCT/CTIS number

2022-500138-27-00

IRAS number

1008068

ClinicalTrials.gov number

NCT05438043

Secondary identifying numbers

54767414MMY3030, CPMS 57832

Study information

Scientific Title

A phase 3b multicenter, open-label study for participants enrolled in daratumumab-containing trials

Study objectives

The primary objective of this study is to collect long-term safety data for participants treated with daratumumab, and to provide ongoing access to daratumumab or other treatment for participants who are currently enrolled in daratumumab or other multiple myeloma program studies that have been completed according to the parent protocol (eg, final analysis has been performed), are actively receiving treatment, and who continue to benefit from treatment.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 05/08/2024, London - Central Research Ethics Committee (3rd Floor 3 Piccadilly Place, London Road, Manchester, M1 3BN , United Kingdom; +44 207 104 8061; londoncentral.rec@hpa.nhs.uk), ref: 24/LO/0503

Study design

Interventional non-randomized

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Safety

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Multiple myeloma

Interventions

Daratumumab will be administered at a dose of 16 mg/kg intravenous (IV) or 1800 mg subcutaneous (SC) as monotherapy or in combination with other study treatment, including but not limited to pomalidomide and dexamethasone, lenalidomide and dexamethasone, carfilzomib, and dexamethasone.

Intervention Type

Drug

Pharmaceutical study type(s)

Therapy

Phase

Phase III

Drug/device/biological/vaccine name(s)

Darzalex [daratumumab]

Primary outcome measure

Measured using patient records at end of study:

1. Number of Participants with Serious Adverse Events (SAEs)
2. Number of Participants with AEs of Special Interest (AESI) (HBV infection)
3. Number of Participants with Pregnancies or Partner Pregnancies
4. Number of Participants with Abnormal Pregnancies as SAE

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

31/01/2022

Completion date

30/04/2026

Eligibility

Key inclusion criteria

1. Participants must:

- be actively receiving daratumumab (either as monotherapy or in combination with other therapy) in a Janssen R&D-sponsored daratumumab study for participants with multiple myeloma which has reached clinical cutoff for final analysis,
- be enrolled in the parent study for a minimum of 12 months prior to rolling over,
- continue to benefit from study treatment,
- not have experienced disease progression or unmanageable toxicity while receiving daratumumab,
- not have met the withdrawal criteria set forth in the parent study, and
- have had the last dose of daratumumab within the previous 3 months.

2. Investigator's assessment that the benefit of continued daratumumab therapy will outweigh the risks.

3. A female participant of childbearing potential must have a negative pregnancy test at screening and must agree to further serum or urine pregnancy tests during the study.

4. A female participant must be either of the following:

- a. Not of childbearing potential, or
- b. Of childbearing potential and practicing at least 1 highly effective method of contraception throughout the study and through 3 months after the last dose of daratumumab.

5. A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study for specified periods after the last dose of study treatment.

6. A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for specified periods after the last dose of study treatment.

If partner is a female of childbearing potential, the male participant must use condom with spermicide and the partner must also be practicing a highly effective method of contraception. A male participant who is vasectomized must still use a condom (with or without spermicide), but the partner is not required to use contraception.

7. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 3 months after receiving the last dose of study treatment.

8. Must sign an informed consent form (ICF; or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.

9. Willing and able to adhere to the lifestyle restrictions specified in this protocol.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

500

Key exclusion criteria

1. Has taken any disallowed therapies or treatment for the disease under study between the completion of the parent study and the planned first dose of study treatment.
2. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
3. Known allergies, hypersensitivity, or intolerance to study treatments or their excipients (refer to the daratumumab IB and local country prescribing information for dexamethasone, carfilzomib, pomalidomide, and lenalidomide).
4. Vaccinated with an investigational vaccine (except for COVID-19) or live attenuated or replicating viral vector vaccines within 4 weeks prior to enrolment.

Date of first enrolment

06/10/2024

Date of final enrolment

31/12/2024

Locations**Countries of recruitment**

Belgium

Denmark

France

Germany

Greece

Italy

Korea, South

Poland

Spain

Türkiye

United Kingdom

United States of America

Study participating centre

-

United Kingdom

-

Sponsor information

Organisation

Janssen-Cilag International N.V.

Sponsor details

Archimedesweg 29

Leiden

Netherlands

2333

+31 715 242 166

ClinicalTrialsEU@its.jnj.com

Sponsor type

Industry

Funder(s)

Funder type

Industry

Funder Name

Cilag

Alternative Name(s)

Janssen-Cilag, Cilag AG

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Switzerland

Results and Publications

Publication and dissemination plan

Peer reviewed scientific journals

Internal report

Conference presentation

Publication on website

Other publication

Submission to regulatory authorities

The Sponsor may share coded information (pseudonymised data) with affiliates, service providers, collaborators, and other research institutions participating in the study or other studies with the same study drug(s).

Intention to publish date

29/01/2027

Individual participant data (IPD) sharing plan

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. Requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

IPD sharing plan summary

Available on request